Mary J. Murphy, M.D.

References

Murphy, M. J. (1998). "Drug failure and HIV resistance create frustrating scenarios for clinicians." Fac Notes (New Orleans La) 10(5): 1-3.

Murphy, M. J. (1998). "Four new antiretroviral medications will soon offer more options to HIV patients." Fac Notes (New Orleans La) 10(4): 1-3.

Murphy, M. J. (1998). "Hydroxyurea may enhance effectiveness of anti-HIV regimens presently in use." Fac Notes (New Orleans La) 10(2): 1-2.

Murphy, M. J. (1998). "New information helps assess the clinical impact of HAART." Fac Notes (New Orleans La) 10(3): 6-7.

Murphy, M. J. (1998). "Update: prophylaxis for HIV opportunistic infections." Fac Notes (New Orleans La) 10(1): 5-6.

Murphy, M. J. (1998). "Will drug resistance testing prove reliable enough to enhance HIV treatments?" Fac Notes (New Orleans La) 10(6): 1-3.

Murphy, M. J. (1999). "Amprenavir may be less cross-resistant with other PIs." HIV Clin 11(5): 1, 7.

Murphy, M. J. (1999). "Metabolic abnormalities are associated with HIV and treatment." Fac Notes (New Orleans La) 11(1): 6-7.

Murphy, M. J. (1999). "New data brings resistance testing closer to routine clinical use." Fac Notes (New Orleans La) 11(3): 6.

Murphy, M. J. (1999). "New versions of antiretroviral guidelines contain some important changes." Fac Notes (New Orleans La) 11(4): 1-3.

Murphy, M. J. (1999). "Preliminary reports on interleukin-2 offer hope for better control of the HIV virus." Fac Notes (New Orleans La) 11(2): 1-2.

Murphy, M. J. (2000). "HIV/HCV co-infection has treatment implications." HIV Clin 12(2): 1, 5.

Murphy, M. J. (2000). "Inexpensive regimen offers hope in developing world." HIV Clin 12(1): 1, 6-7.

Murphy, M. J. (2001). "New information sheds light on the lactemia often associated with HAART therapy." HIV Clin 13(4): 1-3.

Murphy, M. J. (2001). "Newest protease inhibitor Kaletra has a unique profile." HIV Clin 13(1): 6-7.

Murphy MJ. Immune reconstitution disease (IRD) increasing; recognition, management important. HIV Clin. 2004 Fall;16(4):1-3.

Murphy MJ, Wilcox RD. Management of the coinfected patient: human immunodeficiency virus/hepatitis B and human immunodeficiency virus/hepatitis C. Am J Med Sci. 2004 Jul;328(1):26-3

Murphy MJ. Managing HIV/HBV coinfection can challenge some clinicians. HIV Clin. 2003 Fall;15(4):6-9.

Murphy MJ. Upcoming drugs that inhibit viral entry will be a new frontier for antiretroviral therapy. HIV Clin. 2002 Fall;14(4)